SCHEMBL6504804

SCHEMBL6504804

CC(C)(C)OC(=O)N1CCC(N)CC1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.44
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
CHRM2 P08172 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
HPGD P15428 1/20 0.38
GPR119 Q8TDV5 4/20 0.37
USP2 O75604 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
RECQL P46063 1/20 0.36
EPHX1 P07099 1/20 0.36
PTPN2 P17706 1/20 0.36
PTPN1 P18031 1/20 0.36
PTPN6 P29350 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15018797 0.82 CHRM2 (0.42) KDM1AKDM4EMAPTTHRBCHRM2
SCHEMBL25918190 0.82 CHRM2 (0.42) KDM1AKDM4EMAPTTHRBCHRM2
SCHEMBL316518 0.82 CHRM2 (0.42) KDM1AKDM4EMAPTTHRBCHRM2
SCHEMBL16716889 0.82 CHRM2 (0.50) KDM1AKDM4EMAPTTHRBCHRM2
SCHEMBL26984158 0.81 GPR119 (0.46) KDM4EMAPTTHRBCHRM2CHRM1
SCHEMBL102882 0.80 KDM4E (0.39) KDM1AKDM4EMAPTTHRBCHRM2
SCHEMBL22051147 0.79 HSD17B10 (0.47) KDM1AKDM4EMAPTTHRBCHRM2
SCHEMBL22059602 0.79 CHRM2 (0.44) KDM1AKDM4EMAPTTHRBCHRM2
SCHEMBL13929448 0.79 HPGD (0.43) KDM1AKDM4EMAPTTHRBCHRM2
SCHEMBL4102268 0.79 KDM1A (0.45) KDM1AKDM4EMAPTTHRBCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190298705-A1 Chemical Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-10-03 US disclosed
US-20050143372-A1 Compounds, pharmaceutical compositions and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. 2005-06-30 US disclosed
WO-2003037271-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR MILLENNIUM PHARMACEUTICALS,INC. (US) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190298705-A1 Chemical Compounds ATF4, XBP1, EIF2B5 KDM1A 3872/4885KDM4E 3000/4885MAPT 501/4885
US-20050143372-A1 Compounds, pharmaceutical compositions and methods of use therefor CCR8, CCL11, CCR5 KDM1A 4597/4885KDM4E 4617/4885MAPT 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.